Search
forLearn
5 / 801 resultslearn EUK 134
learn pyrithione
learn taurine
learn hairgenyl
Research
5 / 1000+ results
research Short anagen syndrome
Short anagen syndrome involves a hair growth phase lasting 1.5 years.
research Gender Specificity of a Genetic Variant of Androgen Receptor and Risk of Coronary Artery Disease
A genetic variant in the androgen receptor gene increases heart disease risk in women but not in men.
research Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
research P53 Acute west nile virus infection in an SLE patient – diagnostic and therapeutic challenges
SLE patients need careful diagnosis to distinguish infections from disease flares for proper treatment.
research Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based Study
There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.
Community Join
5 / 19 resultscommunity Eirion ET-02( RS 5441) managed to defeat rodents, finally
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
community Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
community ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
community Why does Pelage PP405 receive so much attention, while Eirion ET-02 seems to be almost forgotten?
ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.
community ET-02 Now Recruiting in Texas for Phase 1
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.